{"id":"W2145118120","doi":"10.1016/s1470-2045(13)70162-1","title":"Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":false,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"Celgene","keywords":"Medicine; Tolerability; Response Evaluation Criteria in Solid Tumors; Internal medicine; Regimen; Metastatic Urothelial Carcinoma; Paclitaxel; Clinical endpoint; Adverse effect; Gastroenterology; Progressive disease; Refractory (planetary science); Phases of clinical research; Oncology; Progression-free survival; Chemotherapy; Bladder cancer; Cancer; Clinical trial; Urothelial carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002184668,0.0002343085,0.0008984948,0.0000517419,0.0001041216,0.00001634778,0.0001300696,0.00005249276,0.0005444578],"category_scores_gemma":[0.0000562284,0.000139517,0.000151402,0.0001187854,0.0001545932,0.00006676752,0.00002776547,0.00007076407,0.00006044465],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002931658,"about_ca_system_score_gemma":0.0001691109,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009591978,"about_ca_topic_score_gemma":0.0007145761,"domain_scores_codex":[0.9984183,0.0002163859,0.0004329928,0.0003051928,0.0001580347,0.0004690971],"domain_scores_gemma":[0.9986592,0.0004081238,0.0001765734,0.0004960735,0.0001258672,0.0001341579],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.02948128,0.1284578,0.0636709,0.000580598,0.004869653,0.000322563,0.03337192,0.00001553581,0.6037905,0.0005576562,0.006032946,0.1288487],"study_design_scores_gemma":[0.4018309,0.2683323,0.05514963,0.00006232454,0.007090344,0.000227893,0.01239432,0.001580444,0.1925973,0.002370097,0.05761992,0.0007444522],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914436,0.0006044806,0.00005987929,0.001874266,0.0002735727,0.004740172,0.0001731499,0.00004015903,0.0007907704],"genre_scores_gemma":[0.9956384,0.00001891923,0.0009154154,0.0005820418,0.0004773514,0.001322388,0.00003336222,0.00003526509,0.0009768297],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4111932,"threshold_uncertainty_score":0.5961431,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1066452464032428,"score_gpt":0.3854882551437152,"score_spread":0.2788430087404724,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}